Effect of oral administration of pimobendan in cats with heart failure

Sonya G. Gordon, Ashley B. Saunders, Risa M. Roland, Randolph L. Winter, Lori Drourr, Sarah E. Achen, Crystal D. Hariu, Ryan C. Fries, May M. Boggess, Matthew W. Miller

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction. Design-Retrospective cohort study. Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners. Results-The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardio-myopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11%]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume241
Issue number1
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Effect of oral administration of pimobendan in cats with heart failure'. Together they form a unique fingerprint.

  • Cite this

    Gordon, S. G., Saunders, A. B., Roland, R. M., Winter, R. L., Drourr, L., Achen, S. E., Hariu, C. D., Fries, R. C., Boggess, M. M., & Miller, M. W. (2012). Effect of oral administration of pimobendan in cats with heart failure. Journal of the American Veterinary Medical Association, 241(1), 89-94. https://doi.org/10.2460/javma.241.1.89